A Study to Evaluate the Safety and Efficacy of WS016 in Patients With Hyperkalemia.

NCT06277128 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

140

Enrollment

INDUSTRY

Sponsor class

Conditions

Hyperkalemia

Interventions

DRUG: WS016 3g
DRUG: WS016 6g
DRUG: WS016 12g
DRUG: Matching Placebo

Sponsor

Waterstone Pharmaceutical (Wuhan) Co., LTD.